**SAN DIEGO — November 25, 2025 — Leads & Copy —** PharmaCyte Biotech, Inc. has successfully monetized its stake in Femasys Inc., increasing its cash and marketable securities to approximately $20 million.
The company’s financial position has significantly improved, with cash and marketable securities expected to rise from $13.3 million as of July 31, 2025, to around $20 million after the transaction.
Josh Silverman, PharmaCyte Chief Executive Officer, stated that the monetization demonstrates the effectiveness of the company’s capital allocation approach. He added that the company is committed to deploying shareholder capital intelligently, balancing near-term returns with sustained value creation.
PharmaCyte Biotech has approximately $25 million in marketable securities, according to its most recently filed 10Q, and roughly $20 million in cash, including the proceeds from the Femasys monetization. Despite this strengthened financial position, PharmaCyte’s stock trades at $0.65 per share, with approximately 6.8 million shares outstanding.
PharmaCyte plans to continue pursuing value-accretive investment opportunities and disciplined operational management to enhance shareholder returns.
PharmaCyte Biotech, Inc. is a biotechnology company focused on developing cellular therapies for cancer, diabetes, and other serious diseases. The Company employs a disciplined investment strategy designed to strengthen its financial position and maximize shareholder value through strategic cash deployment.
Josh Silverman, PharmaCyte Chief Executive Officer
Source: PharmaCyte Biotech, Inc.
Source: PharmaCyte Biotech, Inc.
